Enhanced Bioavailability in Shoden® Ashwagandha Linked to Withanolide Glycosides
At 35% withanolide glycosides, Shoden® ashwagandha extract by Arjuna Naturals outperforms other commercial ashwagandha products in clinical study
The randomized, open-label, crossover clinical study, led by
Results of the study revealed striking differences in their pharmacokinetic profiles. Extracts rich in withanolide glycosides—particularly those derived from the plant—demonstrated markedly higher systemic exposure. With Shoden in the lead, these extracts showed longer half-lives, indicating prolonged circulation of active compounds in the body.
New gold standard
"Clinical data now confirm that withanolide glycosides stand out not just for quantity but for quality, with higher bioavailable than other withanolide types," reveals
Shoden® is a highly bioactive extract of ashwagandha, with an industry-leading 35% withanolide glycosides, the key active compounds in the plant. Derived from carefully chosen and validated ashwagandha sources, Arjuna employs a proprietary extraction process to deliver a potent holistic charge of the popular adaptogenic, even at a uniquely low dose of 60 mg.
Also known as "Indian ginseng," the botanical powerhouse has been used in Ayurvedic medicine for centuries as a "rasayana," a rejuvenator, due to its scientifically validated capacity to enhance overall resilience and vitality and promote longevity and mental wellness. Ashwagandha is also noted for its antioxidant, anti-inflammatory, and immunomodulatory properties. Yet Withania extracts available in the market differ considerably in their active compound profiles, analytical methods, plant parts used, manufacturing processes, and recommended dosages. These variables can potentially affect the absorption and therapeutic efficacy of the extracts.
This study marks the latest milestone in Arjuna's robust collection of 12 clinical studies of Shoden. They showcase Shoden's positive role in relieving stress and anxiety and improving sleep quality. Research indicates its mechanisms of action include the ability to regulate the hypothalamus-pituitary-adrenal axis, reducing the stress hormone cortisol and increasing relaxing GABA neurotransmitters. One clinical study highlighting its immunomodulating benefits revealed natural improvements in immune cell markers. And toxicity studies have endorsed its safety.
Shoden outperformed other dominant formulations
"These findings have major implications for both consumers and supplement manufacturers. As ashwagandha continues to gain popularity for its adaptogenic, cognitive, and stress-relieving benefits, the current research underscores the need for more detailed labeling and standardization that goes beyond total withanolide content. Future clinical studies and product formulations should consider the specific withanolide profile—particularly the presence of glycosides—to deliver ashwagandha extracts with maximum efficacy and consistency," concludes Antony.
Shoden has been internationally recognized for the 23 patents attributed to its unique formulation and manufacturing process. It is available in three doses and in various supplement formats, including pills, capsules, and powders. Its low-dose capabilities allow for its seamless integration into functional foods and beverages.
About Arjuna Natural Pvt., Ltd.
For more than a quarter of a century, Arjuna Natural has been
Arjuna will exhibit at Vitafoods Asia 2025, Booth #H34 and also at SupplySide West, Booth #6517.
For further information, please contact:
Company contact Press Contact
Arjuna Natural Pvt NutriPR
Joint Managing Director Tel: +972-9-9742893
Email: [email protected] E-mail: [email protected]
Website: www.arjunanatural.com Website: www.nutripr.com
Photo: https://mma.prnewswire.com/media/2762297/Arjuna_Shoden_Ashwagandha.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/enhanced-bioavailability-in-shoden-ashwagandha-linked-to-withanolide-glycosides-302543638.html
SOURCE Arjuna Natural Ltd.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Beverly Hills Plastic Surgeon Dr. David Sayah Reports Growing Demand for Breast Implant Removal and BBL Reversal
- Michael Rasekhi Announces Scholarship Opportunity for Undergraduate Medical Students Nationwide
- MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for Mucopolysaccharidosis Type IIIB
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share